Sarcoma

Oncologist

Volumn 6, Issue 4, 2001, Pages 333-337

  Maki, Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ASCO; Sarcoma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TRABECTEDIN; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG RECEPTOR BINDING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TUMOR; HUMAN; NAUSEA; NEUROTOXICITY; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SARCOMA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL TRIALS; HUMANS; SARCOMA;

EID: 0034861156     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-4-333     Document Type: Review

References (7)

1. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
2. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
3. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
4. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
5. Preliminary results of a two-arm phase 2 trial of gemcitabine (Gem) in patients (Pts) with gastrointestinal leiomyosarcomas (leios) and other soft-tissue sarcomas (STS)
6. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup
7. Expression of HER2/erbB-2 correlates with survival in osteosarcoma